Benefits
Combined EPA/DHA + vitamin D source
Provides omega-3 EPA and DHA plus vitamin D3 (cholecalciferol) and vitamin A (retinyl esters) in one product. Multi-nutrient profile distinguishes from typical fish oil (which lacks vitamins A and D) and from standalone vitamin D supplements. Particularly relevant for Northern latitude winter supplementation where reduced sun exposure limits endogenous vitamin D synthesis.
Bone health (vitamin D + EPA/DHA)
The vitamin D content supports calcium absorption and bone mineralization, and its best-proven bone effect is preventing and treating rickets and osteomalacia, which are vitamin D deficiency diseases. For an adult who already has adequate vitamin D, the added bone benefit is small. Human evidence that the EPA and DHA meaningfully change bone outcomes is limited.
Corrects vitamin A and D deficiency (immune-relevant)
Vitamin A and vitamin D are both needed for a normal immune response, and correcting a genuine deficiency restores it. Large trials show that vitamin D supplements do not prevent colds or other infections in people who already have adequate levels, so cod liver oil is not an infection preventive for a well-nourished adult. The immune value here is correcting a shortfall, not raising immunity above normal.
Vision support (vitamin A)
Vitamin A (as retinyl esters) supports vision via retinal photopigment regeneration. Cod liver oil traditionally addressed vitamin A deficiency-related vision problems in populations with limited dietary access to retinol.
Omega-3 (EPA/DHA) content, at lower doses than concentrated fish oil
Cod liver oil supplies the same EPA and DHA as fish oil, usually at a lower per-dose amount than concentrated fish oils. A large 2018 Cochrane review (79 trials, over 112,000 people) found that long-chain omega-3 supplements have little or no effect on heart attacks, strokes, or overall death, with at most a small reduction in coronary heart disease events. A healthy person should not expect cod liver oil to prevent heart disease. It is more useful as a multi-nutrient product than as a high-dose omega-3 source.
Mechanism of action
Vitamin A (retinol) mechanisms
Vitamin A (retinyl esters from fish liver) supports vision (retinal photopigment regeneration), immune function, and epithelial maintenance. Critical caveat: cumulative retinol toxicity risk with chronic high doses; teratogenicity at >10,000 IU/day in pregnancy.
Vitamin D3 (cholecalciferol) mechanisms
Vitamin D3 supports calcium absorption, bone mineralization, immune function, and hundreds of vitamin D receptor-mediated downstream effects. Particularly relevant to Northern latitude populations with limited UV exposure for endogenous synthesis.
EPA + DHA mechanisms
Same as fish oil: EPA and DHA omega-3 fatty acids modulate inflammatory eicosanoid balance, support cardiovascular function, and contribute to brain and retinal membrane integrity.
Synergistic nutrient profile
Combined vitamin A + vitamin D + EPA/DHA in natural ratios as found in cod liver. Particularly relevant to Northern latitude winter contexts (low sun → low endogenous vitamin D; cold weather → potentially reduced fish intake). Modern alternatives (vitamin D + fish oil/algae oil) provide more controllable dosing.
Clinical trials
Cod liver oil gained prominence in late 1800s and 1900s for rickets prevention — vitamin D deficiency due to limited sun exposure in northern latitudes.
Clinical population described in trial publication.
Cod liver oil became widely used in the late 1800s and early 1900s to prevent rickets, a vitamin D deficiency disease driven by limited sun exposure at northern latitudes. This is historical public-health observation, not a randomized controlled trial, and it reflects deficiency correction rather than a benefit for people who are already vitamin D replete.
Rheumatoid arthritis adjunct evidence.
Clinical population described in trial publication.
In a double-blind RCT of 97 adults with rheumatoid arthritis, 10 g/day cod liver oil (2.2 g n-3 fatty acids) let 39% cut their NSAID use by more than 30% versus 10% on placebo, with no change in disease activity. This is an NSAID-sparing effect in a diagnosed disease, not evidence of a general joint benefit for healthy people.